NasdaqGS:CRNXPharmaceuticals
Will the CAREFNDR Phase 3 Launch Broaden Crinetics Pharmaceuticals' (CRNX) Long-Term Growth Narrative?
Crinetics Pharmaceuticals recently announced that the first patient has been randomized in its pivotal Phase 3 CAREFNDR trial, a global study evaluating once-daily, oral paltusotine for carcinoid syndrome due to well-differentiated neuroendocrine tumors.
This marks a significant step as paltusotine, already approved in the U.S. for acromegaly, could see its clinical application broadened to another rare disease area if successful.
We'll explore what the launch of this Phase 3 trial could...